254 related articles for article (PubMed ID: 17317612)
1. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI).
Schultz H
Autoimmun Rev; 2007 Mar; 6(4):223-7. PubMed ID: 17317612
[TBL] [Abstract][Full Text] [Related]
2. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies.
Schultz H; Weiss J; Carroll SF; Gross WL
J Leukoc Biol; 2001 Apr; 69(4):505-12. PubMed ID: 11310835
[TBL] [Abstract][Full Text] [Related]
3. BPI-ANCA of pediatric cystic fibrosis patients can impair BPI-mediated killing of E. coli DH5alpha in vitro.
Schultz H; Schinke S; Mosler K; Herlyn K; Schuster A; Gross WL
Pediatr Pulmonol; 2004 Feb; 37(2):158-64. PubMed ID: 14730661
[TBL] [Abstract][Full Text] [Related]
4. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis.
Dorlöchter L; Carlsson M; Olafsdottir EJ; Røksund OD; Rosendahl K; Fluge G
J Cyst Fibros; 2004 Aug; 3(3):179-83. PubMed ID: 15463905
[TBL] [Abstract][Full Text] [Related]
5. BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.
Schultz H; Schinke S; Weiss J; Cerundolo V; Gross WL; Gadola S
Clin Exp Immunol; 2003 Aug; 133(2):252-9. PubMed ID: 12869032
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis.
Carlsson M; Eriksson L; Pressler T; Kornfält R; Mared L; Meyer P; Wiik A; Wieslander J; Segelmark M
J Cyst Fibros; 2007 May; 6(3):228-33. PubMed ID: 17166780
[TBL] [Abstract][Full Text] [Related]
7. A peptide derived from human bactericidal/permeability-increasing protein (BPI) exerts bactericidal activity against Gram-negative bacterial isolates obtained from clinical cases of bovine mastitis.
Chockalingam A; McKinney CE; Rinaldi M; Zarlenga DS; Bannerman DD
Vet Microbiol; 2007 Nov; 125(1-2):80-90. PubMed ID: 17560054
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibodies (ANCA) and associated diseases: clinical relevance of an emerging ANCA target antigen.
Emmi L; Chatzipetrou A
Ann Ital Med Int; 2005; 20(4):205-8. PubMed ID: 16610250
[No Abstract] [Full Text] [Related]
9. Autoantibodies against bactericidal/permeability-increasing protein (BPI) in children with acute pneumonia.
Steiner P; Otth M; Casaulta C; Aebi C
FEMS Immunol Med Microbiol; 2009 Nov; 57(2):125-8. PubMed ID: 19702878
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease.
Carlsson M; Shukla S; Petersson AC; Segelmark M; Hellmark T
J Cyst Fibros; 2011 Jul; 10(4):265-71. PubMed ID: 21463973
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin.
Rotschild M; Elias N; Berkowitz D; Pollak S; Shinawi M; Beck R; Bentur L
Clin Exp Med; 2005 Jul; 5(2):80-5. PubMed ID: 16096858
[TBL] [Abstract][Full Text] [Related]
13. A novel role for the bactericidal/permeability increasing protein in interactions of gram-negative bacterial outer membrane blebs with dendritic cells.
Schultz H; Hume J; Zhang DS; Gioannini TL; Weiss JP
J Immunol; 2007 Aug; 179(4):2477-84. PubMed ID: 17675509
[TBL] [Abstract][Full Text] [Related]
14. The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.
Schultz H; Weiss JP
Clin Chim Acta; 2007 Sep; 384(1-2):12-23. PubMed ID: 17678885
[TBL] [Abstract][Full Text] [Related]
15. Anti-neutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in patients with rheumatoid arthritis and their correlation with bronchial involvement.
Wada Y; Kuroda T; Murasawa A; Nakano M; Narita I
Mod Rheumatol; 2010 Jun; 20(3):252-6. PubMed ID: 20107854
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity.
Marra MN; Wilde CG; Griffith JE; Snable JL; Scott RW
J Immunol; 1990 Jan; 144(2):662-6. PubMed ID: 2295804
[TBL] [Abstract][Full Text] [Related]
17. Deficient expression of bactericidal/permeability-increasing protein in immunocompromised hosts: translational potential of replacement therapy.
Palmer CD; Guinan EC; Levy O
Biochem Soc Trans; 2011 Aug; 39(4):994-9. PubMed ID: 21787336
[TBL] [Abstract][Full Text] [Related]
18. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gram-negative bacteria and lipopolysaccharide.
Elsbach P; Weiss J
Immunobiology; 1993 Apr; 187(3-5):417-29. PubMed ID: 8330906
[TBL] [Abstract][Full Text] [Related]
19. Prospects for use of recombinant BPI in the treatment of gram-negative bacterial infections.
Elsbach P; Weiss J
Infect Agents Dis; 1995 Jun; 4(2):102-9. PubMed ID: 7613727
[TBL] [Abstract][Full Text] [Related]
20. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.
Aichele D; Schnare M; Saake M; Röllinghoff M; Gessner A
Infect Immun; 2006 Aug; 74(8):4708-14. PubMed ID: 16861658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
